What are the limitations of the doac dose selector?

While the doac dose selector is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the doac dose selector to ensure safe bedside use and optimal diagnostic accuracy.

How does the doac dose selector compare to other hematology scores?

The doac dose selector is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the doac dose selector free to use?

Yes. OpiCalc provides the doac dose selector completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

DOAC Dose Selector

DOAC Dosing: Guidelines vary by Indication (AF vs. VTE) and Patient Factors. Ensure CrCl is calculated via Cockcroft-Gault for accurate dosing.

1. Select Agent

2. Indication

3. Patient Factors

Standard Registered Dose

5 mg bid

Can be taken with or without food.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Determining the standard and reduced doses for Direct Oral Anticoagulants (DOACs).

Applying dose-reduction criteria for elderly, underweight, or renal-impaired patients.

Differentiating between Atrial Fibrillation (stroke prevention) and VTE (DVT/PE treatment) dosing.

Common DOACs

Includes Apixaban (Eliquis), Rivaroxaban (Xarelto), Edoxaban (Lixiana/Savaysa), and Dabigatran (Pradaxa).

Section 2

Formula & Logic

Apixaban (AF)

Criteria	Dose
Standard	5 mg bid
If ≥ 2 of: Age ≥ 80, Wt ≤ 60kg, Cr ≥ 1.5 mg/dL	2.5 mg bid

Rivaroxaban (AF)

Criteria	Dose
CrCl > 50 mL/min	20 mg qd (with food)
CrCl 15 - 50 mL/min	15 mg qd (with food)

Section 3

VTE Treatment

Apixaban (VTE)

Initial 7 days: 10 mg bid.

Maintenance (> 7 days): 5 mg bid.

Extended (> 6 months): 2.5 mg bid.

Rivaroxaban (VTE)

Initial 21 days: 15 mg bid.

Maintenance (> 21 days): 20 mg qd.

Extended (> 6 months): 10 mg qd.

Section 4

Pearls/Pitfalls

The Edoxaban Paradox

Edoxaban is unique in that it is contraindicated (or has reduced efficacy) in patients with supranormal renal function (CrCl > 95 mL/min) because the drug is cleared too rapidly to maintain therapeutic levels.

Dabigatran Storage

Dabigatran capsules must remain in their original blister pack until use. Exposure to humidity causes rapid degradation.

Section 5

Evidence Appraisal

Primary Trials

Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE).

Granger CB et al. • NEJM. 2011;365(11):981-92.

View Source

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF).

Patel MR et al. • NEJM. 2011;365(10):883-91.

View Source

Section 6

Literature

Consensus

Guidelines from the EHRA (European Heart Rhythm Association) and ISTH provide standardized dosing tables to prevent prescribing errors, which are common with complex DOAC regimens.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Determining the standard and reduced doses for Direct Oral Anticoagulants (DOACs).

Applying dose-reduction criteria for elderly, underweight, or renal-impaired patients.

Differentiating between Atrial Fibrillation (stroke prevention) and VTE (DVT/PE treatment) dosing.

Common DOACs

Includes Apixaban (Eliquis), Rivaroxaban (Xarelto), Edoxaban (Lixiana/Savaysa), and Dabigatran (Pradaxa).

Section 2

Formula & Logic

Apixaban (AF)

Criteria	Dose
Standard	5 mg bid
If ≥ 2 of: Age ≥ 80, Wt ≤ 60kg, Cr ≥ 1.5 mg/dL	2.5 mg bid

Rivaroxaban (AF)

Criteria	Dose
CrCl > 50 mL/min	20 mg qd (with food)
CrCl 15 - 50 mL/min	15 mg qd (with food)

Section 3

VTE Treatment

Apixaban (VTE)

Initial 7 days: 10 mg bid.

Maintenance (> 7 days): 5 mg bid.

Extended (> 6 months): 2.5 mg bid.

Rivaroxaban (VTE)

Initial 21 days: 15 mg bid.

Maintenance (> 21 days): 20 mg qd.

Extended (> 6 months): 10 mg qd.

Section 4

Pearls/Pitfalls

The Edoxaban Paradox

Dabigatran Storage

Dabigatran capsules must remain in their original blister pack until use. Exposure to humidity causes rapid degradation.

Section 5

Evidence Appraisal

Primary Trials

Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE).

Granger CB et al. • NEJM. 2011;365(11):981-92.

View Source

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF).

Patel MR et al. • NEJM. 2011;365(10):883-91.

View Source

Section 6

Literature

Consensus

Guidelines from the EHRA (European Heart Rhythm Association) and ISTH provide standardized dosing tables to prevent prescribing errors, which are common with complex DOAC regimens.

Last Comprehensive Review: 2026

Related Hematology Tools

NIH Chronic GvHD Scoring

Sickle Cell Disease Risk

Thalassaemia Transfusion Threshold

NTDT Iron Burden Estimator

HbS Percentage Target Calculator

ITP Bleeding Score

IWG ITP Response Criteria

WHO Bleeding Scale

Thrombocytopaenia Differential

Warfarin Dose Calculator

Have feedback about this calculator?Let us know.

DOAC Dose Selector

DOAC Dosing: Guidelines vary by Indication (AF vs. VTE) and Patient Factors. Ensure CrCl is calculated via Cockcroft-Gault for accurate dosing.

1. Select Agent

2. Indication

3. Patient Factors

Standard Registered Dose

5 mg bid

Can be taken with or without food.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Determining the standard and reduced doses for Direct Oral Anticoagulants (DOACs).

Applying dose-reduction criteria for elderly, underweight, or renal-impaired patients.

Differentiating between Atrial Fibrillation (stroke prevention) and VTE (DVT/PE treatment) dosing.

Common DOACs

Includes Apixaban (Eliquis), Rivaroxaban (Xarelto), Edoxaban (Lixiana/Savaysa), and Dabigatran (Pradaxa).

Section 2

Formula & Logic

Apixaban (AF)

Criteria	Dose
Standard	5 mg bid
If ≥ 2 of: Age ≥ 80, Wt ≤ 60kg, Cr ≥ 1.5 mg/dL	2.5 mg bid

Rivaroxaban (AF)

Criteria	Dose
CrCl > 50 mL/min	20 mg qd (with food)
CrCl 15 - 50 mL/min	15 mg qd (with food)

Section 3

VTE Treatment

Apixaban (VTE)

Initial 7 days: 10 mg bid.

Maintenance (> 7 days): 5 mg bid.

Extended (> 6 months): 2.5 mg bid.

Rivaroxaban (VTE)

Initial 21 days: 15 mg bid.

Maintenance (> 21 days): 20 mg qd.

Extended (> 6 months): 10 mg qd.

Section 4

Pearls/Pitfalls

The Edoxaban Paradox

Dabigatran Storage

Dabigatran capsules must remain in their original blister pack until use. Exposure to humidity causes rapid degradation.

Section 5

Evidence Appraisal

Primary Trials

Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE).

Granger CB et al. • NEJM. 2011;365(11):981-92.

View Source

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF).

Patel MR et al. • NEJM. 2011;365(10):883-91.

View Source

Section 6

Literature

Consensus

Guidelines from the EHRA (European Heart Rhythm Association) and ISTH provide standardized dosing tables to prevent prescribing errors, which are common with complex DOAC regimens.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Determining the standard and reduced doses for Direct Oral Anticoagulants (DOACs).

Applying dose-reduction criteria for elderly, underweight, or renal-impaired patients.

Differentiating between Atrial Fibrillation (stroke prevention) and VTE (DVT/PE treatment) dosing.

Common DOACs

Includes Apixaban (Eliquis), Rivaroxaban (Xarelto), Edoxaban (Lixiana/Savaysa), and Dabigatran (Pradaxa).

Section 2

Formula & Logic

Apixaban (AF)

Criteria	Dose
Standard	5 mg bid
If ≥ 2 of: Age ≥ 80, Wt ≤ 60kg, Cr ≥ 1.5 mg/dL	2.5 mg bid

Rivaroxaban (AF)

Criteria	Dose
CrCl > 50 mL/min	20 mg qd (with food)
CrCl 15 - 50 mL/min	15 mg qd (with food)

Section 3

VTE Treatment

Apixaban (VTE)

Initial 7 days: 10 mg bid.

Maintenance (> 7 days): 5 mg bid.

Extended (> 6 months): 2.5 mg bid.

Rivaroxaban (VTE)

Initial 21 days: 15 mg bid.

Maintenance (> 21 days): 20 mg qd.

Extended (> 6 months): 10 mg qd.

Section 4

Pearls/Pitfalls

The Edoxaban Paradox

Dabigatran Storage

Dabigatran capsules must remain in their original blister pack until use. Exposure to humidity causes rapid degradation.

Section 5

Evidence Appraisal

Primary Trials

Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE).

Granger CB et al. • NEJM. 2011;365(11):981-92.

View Source

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF).

Patel MR et al. • NEJM. 2011;365(10):883-91.

View Source

Section 6

Literature

Consensus

Guidelines from the EHRA (European Heart Rhythm Association) and ISTH provide standardized dosing tables to prevent prescribing errors, which are common with complex DOAC regimens.

Last Comprehensive Review: 2026

Related Hematology Tools

NIH Chronic GvHD Scoring

Sickle Cell Disease Risk

Thalassaemia Transfusion Threshold

NTDT Iron Burden Estimator

HbS Percentage Target Calculator

ITP Bleeding Score

IWG ITP Response Criteria

WHO Bleeding Scale

Thrombocytopaenia Differential

Warfarin Dose Calculator

Have feedback about this calculator?Let us know.